CryoLife this week said it signed a distribution agreement with Misonix where Misonix will have exclusive commercialization rights of NeoPatch.
The NeoPatch, made by CryoLife, is a dehydrated and terminally sterilized chorioamniotic allograft that is made from human placental membrane. It is designed to treat a wide range of indications outside of cardiac and vascular surgery.
Get the full story on our sister site, Medical Design & Outsourcing.